Literature DB >> 22640768

The genetic basis of addictive disorders.

Francesca Ducci1, David Goldman.   

Abstract

Addictions are common, chronic, and relapsing diseases that develop through a multistep process. The impact of addictions on morbidity and mortality is high worldwide. Twin studies have shown that the heritability of addictions ranges from 0.39 (hallucinogens) to 0.72 (cocaine). Twin studies indicate that genes influence each stage from initiation to addiction, although the genetic determinants may differ. Addictions are by definition the result of gene × environment interaction. These disorders, which are in part volitional, in part inborn, and in part determined by environmental experience, pose the full range of medical, genetic, policy, and moral challenges. Gene discovery is being facilitated by a variety of powerful approaches, but is in its infancy. It is not surprising that the genes discovered so far act in a variety of ways: via altered metabolism of drug (the alcohol and nicotine metabolic gene variants), via altered function of a drug receptor (the nicotinic receptor, which may alter affinity for nicotine but as discussed may also alter circuitry of reward), and via general mechanisms of addiction (genes such as monoamine oxidase A and the serotonin transporter that modulate stress response, emotion, and behavioral control). Addiction medicine today benefits from genetic studies that buttress the case for a neurobiologic origin of addictive behavior, and some general information on familially transmitted propensity that can be used to guide prevention. A few well-validated, specific predictors such as OPRM1, ADH1B, ALDH2, CHRNA5, and CYP26 have been identified and can provide some specific guidance, for example, to understand alcohol-related flushing and upper GI cancer risk (ADH1B and AKLDH2), variation in nicotine metabolism (CYP26), and, potentially, naltrexone treatment response (OPRM1). However, the genetic predictors available are few in number and account for only a small portion of the genetic variance in liability, and have not been integrated into clinical nosology or care.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22640768      PMCID: PMC3506170          DOI: 10.1016/j.psc.2012.03.010

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  131 in total

Review 1.  The utility of the non-human primate; model for studying gene by environment interactions in behavioral research.

Authors:  C S Barr; T K Newman; M L Becker; C C Parker; M Champoux; K P Lesch; D Goldman; S J Suomi; J D Higley
Journal:  Genes Brain Behav       Date:  2003-12       Impact factor: 3.449

2.  Family transmission and heritability of externalizing disorders: a twin-family study.

Authors:  Brian M Hicks; Robert F Krueger; William G Iacono; Matt McGue; Christopher J Patrick
Journal:  Arch Gen Psychiatry       Date:  2004-09

3.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.

Authors:  Jingshan Chen; Barbara K Lipska; Nader Halim; Quang D Ma; Mitsuyuki Matsumoto; Samer Melhem; Bhaskar S Kolachana; Thomas M Hyde; Mary M Herman; Jose Apud; Michael F Egan; Joel E Kleinman; Daniel R Weinberger
Journal:  Am J Hum Genet       Date:  2004-09-27       Impact factor: 11.025

4.  Human catechol-O-methyltransferase down-regulation by estradiol.

Authors:  H Jiang; T Xie; D B Ramsden; S L Ho
Journal:  Neuropharmacology       Date:  2003-12       Impact factor: 5.250

5.  The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women.

Authors:  Kenneth S Kendler; Carol A Prescott; John Myers; Michael C Neale
Journal:  Arch Gen Psychiatry       Date:  2003-09

6.  Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia.

Authors:  Terry E Goldberg; Michael F Egan; Tonya Gscheidle; Richard Coppola; Thomas Weickert; Bhaskar S Kolachana; David Goldman; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2003-09

7.  Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity.

Authors:  P D Scanlon; F A Raymond; R M Weinshilboum
Journal:  Science       Date:  1979-01-05       Impact factor: 47.728

8.  Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan
Journal:  Arch Gen Psychiatry       Date:  2004-08

9.  Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; W June Ruan; Roger P Pickering
Journal:  Arch Gen Psychiatry       Date:  2004-04

10.  Primary anxiety disorders and the development of subsequent alcohol use disorders: a 4-year community study of adolescents and young adults.

Authors:  P Zimmermann; H U Wittchen; M Höfler; H Pfister; R C Kessler; R Lieb
Journal:  Psychol Med       Date:  2003-10       Impact factor: 7.723

View more
  80 in total

Review 1.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

Review 2.  Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.

Authors:  Miles D Thompson; George A Kenna
Journal:  Alcohol Alcohol       Date:  2015-08-26       Impact factor: 2.826

3.  Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry.

Authors:  Dina Popova; Nidhi Desai; Julie A Blendy; Zhiping P Pang
Journal:  J Neurosci       Date:  2019-05-20       Impact factor: 6.167

4.  Characterization of DSM-IV Opioid Dependence Among Individuals of European Ancestry.

Authors:  Leslie A Brick; Lauren Micalizzi; Valerie S Knopik; Rohan H C Palmer
Journal:  J Stud Alcohol Drugs       Date:  2019-05       Impact factor: 2.582

5.  The Benefits of Genetic Addiction Risk Score (GARS) Testing in Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Edward J Modestino; Marjorie Gondre-Lewis; Edwin J Chapman; Jennifer Neary; David Siwicki; David Baron; Mary Hauser; David E Smith; Alphonse Kenison Roy; Panayotis K Thanos; Bruce Steinberg; Thomas McLaughlin; Lyle Fried; Debmalya Barh; Georgia A Dunston; Rajendra D Badgaiyan
Journal:  Int J Genom Data Min       Date:  2018-01-15

6.  Forgiving the sins of the fathers.

Authors:  Michael D Scofield; Peter W Kalivas
Journal:  Nat Neurosci       Date:  2013-01       Impact factor: 24.884

7.  Non-genetic factors that influence methamphetamine intake in a genetic model of differential methamphetamine consumption.

Authors:  A M Stafford; C Reed; T J Phillips
Journal:  Psychopharmacology (Berl)       Date:  2020-08-24       Impact factor: 4.530

Review 8.  Reducing substance use during adolescence: a translational framework for prevention.

Authors:  Jessica J Stanis; Susan L Andersen
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 9.  Behavioral Genetics in Criminal and Civil Courts.

Authors:  Maya Sabatello; Paul S Appelbaum
Journal:  Harv Rev Psychiatry       Date:  2017 Nov/Dec       Impact factor: 3.732

10.  GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM): LESSONS LEARNED FROM AMERICA.

Authors:  Kenneth Blum; Edward J Modestino; Marjorie C Gondré-Lewis; Jennifer Neary; David Siwicki; Mary Hauser; Debmalya Barh; Bruce Steinberg; Rajendra D Badgaiyan
Journal:  Precis Med (Bangalore)       Date:  2017-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.